Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Gilead Sciences, seeing a 22% boost ... bolstered by the still high demand for their weight-loss and diabetes drugs, which ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

REMS programmes are typically implemented after drug approval when the FDA determines that a medication needs to be closely ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

A mere $20 stock of Gilead in 2011 saw a considerable momentum in the years ... Some recovery was aided by the contribution ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

where a jury could find he offered sufficient evidence to suggest he was terminated for refusing to obtain a confidential memo from a hospital and refusing to offer kickbacks or remuneration to induce ...

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...